SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Moleculin Biotech, Inc. (MBRX) Q3 Net Loss Falls to $6.5M; MIRACLE Part A Treatment Complete

Moleculin reported Q3 2026 net loss of approximately $6.5M, versus $25.4M a year earlier, mainly because the prior-year period included a $20.6M non-cash warrant-liability loss. Treatment of all 90 MIRACLE Part A patients is complete; data remain on track for Q1 2027.Material DetailsContext by AI A…

MBRX

Related stories